LABS vs. HLS, TGOD, NINE, SUGR, WMD, MDP, HEXO, VIR, ZOM, and META
Should you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), SugarBud Craft Growers (SUGR), WeedMD (WMD), Medexus Pharmaceuticals (MDP), HEXO (HEXO), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), and Meta Growth (META). These companies are all part of the "drug manufacturers - specialty & generic" industry.
MediPharm Labs vs.
MediPharm Labs (TSE:LABS) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk.
MediPharm Labs has higher earnings, but lower revenue than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.
In the previous week, MediPharm Labs had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for MediPharm Labs and 0 mentions for HLS Therapeutics. MediPharm Labs' average media sentiment score of 0.88 beat HLS Therapeutics' score of 0.00 indicating that MediPharm Labs is being referred to more favorably in the media.
0.7% of MediPharm Labs shares are owned by institutional investors. Comparatively, 65.2% of HLS Therapeutics shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by company insiders. Comparatively, 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
MediPharm Labs has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.
MediPharm Labs has a net margin of -30.56% compared to HLS Therapeutics' net margin of -38.70%. MediPharm Labs' return on equity of -24.41% beat HLS Therapeutics' return on equity.
HLS Therapeutics received 9 more outperform votes than MediPharm Labs when rated by MarketBeat users. However, 65.79% of users gave MediPharm Labs an outperform vote while only 65.38% of users gave HLS Therapeutics an outperform vote.
Summary
MediPharm Labs beats HLS Therapeutics on 9 of the 15 factors compared between the two stocks.
Get MediPharm Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediPharm Labs Competitors List
Related Companies and Tools
This page (TSE:LABS) was last updated on 3/3/2025 by MarketBeat.com Staff
